The European Commission Has Adopted A Positive Decision For The Designation Of Agios Pharmaceuticals' Mitapivat As An Orphan Medicinal Product For Sickle Cell Disease
The European Commission Has Adopted A Positive Decision For The Designation Of Agios Pharmaceuticals' Mitapivat As An Orphan Medicinal Product For Sickle Cell Disease
歐洲委員會已就將Agios Pharmaceuticals的Mitapivat指定爲鐮狀細胞貧血的孤兒藥物作出了積極決定
. Earlier, in November 2020, the U.S. Food and Drug Administration (FDA) also granted orphan drug designation to mitapivat for sickle cell disease.
。此前，在2020年11月，美國食品藥品監督管理局（FDA）還授予米塔皮瓦特治療鐮狀細胞病的孤兒藥資格。
資訊熱榜
更新時間